期刊文献+

血清乙肝病毒DNA煮沸抽提法的建立和应用 被引量:5

Establishment and application of boiling method to extract HBV DNA from serum sample
下载PDF
导出
摘要 目的 建立一种简便的血清HBV DNA抽提方法一煮沸抽提法,并将其应用于巢式PCR扩增。方法 选取16份CHB血清,分别应用直接煮沸法和异硫氰酸胍-酚/氯仿法进行HBV DNA抽提后,进行荧光定量PCR测定;并以煮沸法抽提样品为模板,进行HBV DNA P区部分片段巢式PCR扩增。结果 将上述两种抽提方法的荧光定量PCR结果取对数后进行直线相关分析和配对样本t检验,结果显示:两种方法的定量PCR结果之间存在良好的相关性(r=0.696,P=0.003),且二者定量PCR结果无差异(P=0.663)。16份标本巢式PCR扩增均为阳性,PCR产物分子量大小与预期值相符。结论 直接煮沸法抽提HBV DNA,简便、快速、效果好,适用于HBV的科研和临床检测工作。 Objective To establish a new method to extract HBV DNA from serum sample for nested PCR.Methods The DNA templates from 16 serum samples with different HBV DNA concentration were prepared by boiling serum to release HBV DNA from the virus particles and purifying the nucleic acid from serum. Then, the difference of HBV DNA quantitative were valued by fluorescence quantitative PCR. Finally, the DNA templates prepared by boiling method were used to nested PCR for amplifying segment of HBV P gene. Results The HBV DNA quantitative values by fluorescence quantitative PCR using the templates prepared by the two methods were positively correlative ( r = 0.696, P = 0 .003) and not significantly different ( P - 0.663) . The results of nested PCR of 16 DNA templates by boiling method were positive. Conclusions The boiling method to extract HBV DNA from serum sample for PCR is convenient, rapid and reliable, and can be applied to scientific research and clinical detection of HBV.
机构地区 北京地坛医院
出处 《胃肠病学和肝病学杂志》 CAS 2003年第4期381-382,共2页 Chinese Journal of Gastroenterology and Hepatology
基金 首都医学发展科研基金(2002-3046)
关键词 血清 乙型肝炎病毒 煮沸抽提 HBV DNA 聚合酶链反应 乙型肝炎 Serum HBV DNA Extract by boiling
  • 相关文献

参考文献4

  • 1C.W.迪芬巴赫 G.S.德维克斯勒.PCR技术实验指南[M].北京:科学出版社,1998.71,49,207-208.
  • 2闫杰,王磊,徐皖苏,张照华,杜以真,王耀宗.拉米夫定治疗中乙肝病毒多聚酶YMDD变异对患者临床经过的影响[J].山东医科大学学报,2001,39(2):171-172. 被引量:13
  • 3F.奥斯伯等著.颜子颖 王海林译.精编分子生物学实验指南[M].北京:科学出版社,1998.18-19.
  • 4吴乃虎.基因工程原理:第2版[M].北京:科学出版社,1998.103.

二级参考文献6

  • 1[1]Cane PA, Mutimer D, Ratcliffe D, et al. Analysis of hepatitsB virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation[J]. Antivir Ther, 1999,4(1):7
  • 2[2]Ben Ari Z, Zemel R, Kazetsker A, et al. Efficacy of lamivudine in patients with hepatitis B virus precoremutant infection before and after liver transplantation [J].Am J Gastroenterol, 1999,94(3):663
  • 3[3]Dienstag JL,Schiff ER,Mitchell M,et al. Extended lamivudine retreatment for chronic hepatitis B:maintenance of viral suppression after discontinuation oftherapy[J]. Hepatology 1999,30(4): 1082
  • 4[4]Ben Ari Z,Pappo O,Zemel R,et al. Association of lamivudine resistance in recurrent hepatitis B after liver transplantation with advanced hepaticfibrosis[J].Transplan tation, 1999,68(2):232
  • 5[5]Bessesen M,Ives D,Condreay L,et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine[J]. Clin Infect Dis, 1999,28(5):1032
  • 6[6]Peters MG,Singer G,Howard T,et al. Fulminant hepatic failure resulting form lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivosil and hepatitis B immune globulin[J].Transplantation, 1999,68(12):1912

共引文献24

同被引文献46

  • 1郑链跃,陶爱萍.慢性乙型肝炎应用拉米夫定抗病毒治疗的疗效分析[J].中国生化药物杂志,2014,34(2):145-146. 被引量:16
  • 2袁久志,吴立军.青龙胆属药用植物研究进展[J].中药研究与信息,2005,7(1):14-17. 被引量:3
  • 3李文鹏,李彤,庄辉.乙型肝炎病毒对拉米夫定耐药的研究进展[J].传染病信息,2007,20(1):32-35. 被引量:9
  • 4朱万孚.鸭乙型肝炎动物模型的研究[J].北京医科大学学报,1987,19:223-223.
  • 5罗献瑞 赵素云.中国防已科资料[J].广西植物,1986,6:51-53.
  • 6Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir - resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine [ J ]. Antimicrob Agents Chemother, 2004,48 (9) : 3498 - 3507.
  • 7Gunther S, Li BC, Miska S, et al. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients [ J ]. J Virol, 1995,69(9) :5437 - 5444.
  • 8Nagasaki F, Niitsuma H, Ueno Y, et al. The high incidence of the emergence of entecavir - resistant mutants among patients infected with lamivudinc - resistant hepatitis B virus [ J ]. Tohoku J Exp Med,2007,213 (2) : 181 - 186.
  • 9Das K, Xiong X, Yang H, et al. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC) [J]. J Virol, 2001, 75 (10) : 4771 - 4779.
  • 10Tenney DJ, Rose RE, Baldick C J, et al. Two - year assessment of entecavir resistance in lamivudine - refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present [ J]. Antimicrob Agents Chemother, 2007,51 ( 3 ) : 902 - 911.

引证文献5

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部